Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vigil Neuroscience, Inc.
Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi
June 27, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present in Upcoming June Investor Conferences
May 30, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference
May 08, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting
April 17, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 26, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer
March 20, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting
March 13, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days
March 12, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
March 06, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024
February 29, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference
February 07, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones
January 03, 2024
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference
November 22, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE
November 16, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease
October 17, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
September 26, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting
September 11, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program
September 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference
September 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer
August 07, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference
June 01, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors
May 09, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)
May 08, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101
March 30, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Vigil Neuroscience to Present at Stifel 2023 CNS Days
March 22, 2023
From
Vigil Neuroscience, Inc.
Via
GlobeNewswire
Tickers
VIGL
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.